Patents Assigned to EIGER BIOPHARMACEUTICALS, INC.
  • Treatment of hepatitis delta virus infection
    Patent number: 10076512
    Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: September 18, 2018
    Assignee: Eiger BioPharmaceuticals, Inc.
    Inventors: David A. Cory, Ingrid Choong, Jeffrey S. Glenn
  • QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES
    Publication number: 20170281611
    Abstract: Provided herein are quinolines, e.g., a compound of Formula (I) or (IB), pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of an endoplasmic reticulum stress-caused disease. Also provided herein are methods of their use for reducing endoplasmic reticulum stress and modulating the activity of a sarcoplasmic/endoplasmic reticulum Ca2+ ATPase.
    Type: Application
    Filed: March 20, 2015
    Publication date: October 5, 2017
    Applicant: Eiger Biopharmaceuticals, Inc.
    Inventor: Russell DAHL
  • TREATMENT OF HEPATITIS DELTA VIRUS INFECTION
    Publication number: 20170042862
    Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.
    Type: Application
    Filed: October 26, 2016
    Publication date: February 16, 2017
    Applicant: Eiger BioPharmaceuticals, Inc.
    Inventors: David A. Cory, Ingrid Choong, Jeffrey S. Glenn
  • AZAINDAZOLES TO TREAT FLAVIVIRIDAE VIRUS INFECTION
    Publication number: 20120232062
    Abstract: Azaindazole compounds are useful for treating Flaviviridae virus infection, including HCV infection.
    Type: Application
    Filed: October 19, 2010
    Publication date: September 13, 2012
    Applicant: EIGER BIOPHARMACEUTICALS, INC.
    Inventors: Wenjin Yang, Ingrid Choong